Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the B∼FIT Cohort

Hormones and Cancer

Volumn 7, Issue 1, 2016, Pages 49-64

  Dallal, Cher M ^a,b   Lacey, James V ^c   Pfeiffer, Ruth M ^b   Bauer, Douglas C ^d,g   Falk, Roni T ^b   Buist, Diana S M ^e   Cauley, Jane A ^f   Hue, Trisha F ^g   LaCroix, Andrea Z ^h   Tice, Jeffrey A ^d   Veenstra, Timothy D ^i,j   Xu, Xia ^j   Brinton, Louise A ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GROUP HEALTH RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF SAN FRANCISCO   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ C2N Diagnostics   (United States)

^j FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; ESTRADIOL; ESTROGEN; ESTRONE;

AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; METABOLITE; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; BLOOD; ENDOMETRIAL NEOPLASMS; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TANDEM MASS SPECTROMETRY;

AGED; CHROMATOGRAPHY, LIQUID; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; OVARIAN NEOPLASMS; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TANDEM MASS SPECTROMETRY;

EID: 84955744115     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-015-0237-y     Document Type: Article

References (35)

1. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, Peeters PH et al (2008) Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 15(2):485–497. doi:10.1677/ERC-07-0064
2. Brinton LA, Felix AS (2014) Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol 142:83–89. doi:10.1016/j.jsbmb.2013.05.001
3. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–591. doi:10.1038/nrc1408
4. Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11(12):1531–1543
5. Lukanova A, Kaaks R (2005) Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 14(1):98–107
6. Collaborative Group on Epidemiological Studies of Ovarian, Cancer (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. doi:10.1016/S0140-6736(14)61687-1
7. Zeleniuch-Jacquotte A, Shore RE, Afanasyeva Y, Lukanova A, Sieri S, Koenig KL, Idahl A et al (2011) Postmenopausal circulating levels of 2- and 16α-hydroxyestrone and risk of endometrial cancer. Br J Cancer 105(9):1458–1464. doi:10.1038/bjc.2011.381
8. Audet-Walsh E, Lepine J, Gregoire J, Plante M, Caron P, Tetu B, Ayotte P et al (2011) Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab 96(2):E330–E339. doi:10.1210/jc.2010-2050
9. Lippert TH, Seeger H, Mueck AO (2000) The impact of endogenous estradiol metabolites on carcinogenesis. Steroids 65(7):357–369
10. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P et al (2006) Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 1766(1):63–78. doi:10.1016/j.bbcan.2006.03.001
11. Mueck AO, Seeger H, Lippert TH (2002) Estradiol metabolism and malignant disease. Maturitas 43(1):1–10
12. Fishman J, Schneider J, Hershcope RJ, Bradlow HL (1984) Increased estrogen-16 alpha-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem 20(4B):1077–1081
13. Bradlow HL, Sepkovic DW, Klug T, Osborne MP (1998) Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids 63(7–8):406–413
14. Swaneck GE, Fishman J (1988) Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci U S A 85(21):7831–7835
15. Seeger H, Wallwiener D, Kraemer E, Mueck AO (2006) Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 54(1):72–77. doi:10.1016/j.maturitas.2005.08.010
16. Lippert C, Seeger H, Mueck AO (2003) The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci 72(8):877–883
17. Liehr JG (1990) Genotoxic effects of estrogens. Mutat Res 238(3):269–276
18. Zhang Y, Gaikwad NW, Olson K, Zahid M, Cavalieri EL, Rogan EG (2007) Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism 56(7):887–894. doi:10.1016/j.metabol.2007.03.001
19. Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, Buys SS et al (2012) Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 104(4):326–339. doi:10.1093/jnci/djr531
20. Falk RT, Brinton LA, Dorgan JF, Fuhrman BJ, Veenstra TD, Xu X, Gierach GL (2013) Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Res 15(2):R34. doi:10.1186/bcr3416
21. Samavat H, Kurzer MS (2014) Estrogen metabolism and breast cancer. Cancer Lett. doi:10.1016/j.canlet.2014.04.018
22. Dallal CM, Tice JA, Buist DS, Bauer DC, Lacey JV Jr, Cauley JA, Hue TF et al (2014) Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B∼FIT. Carcinogenesis 35(2):346–355. doi:10.1093/carcin/bgt367
23. Dallal CM, Stone RA, Cauley JA, Ness RB, Vogel VG, Fentiman IS, Fowke JH et al (2012) Urinary estrogen metabolites and breast cancer: a combined analysis of individual level data. Int J Biol Markers. doi:10.5301/JBM.2012.9353
24. Zhao H, Jiang Y, Liu Y, Yun C, Li L (2014) Endogenous estrogen metabolites as biomarkers for endometrial cancer via a novel method of liquid chromatography-mass spectrometry with hollow fiber liquid-phase microextraction. Horm Metab Res. doi:10.1055/s-0034-1371865
25. Lukanova A, Lundin E, Akhmedkhanov A, Micheli A, Rinaldi S, Zeleniuch-Jacquotte A, Lenner P et al (2003) Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer 104(5):636–642. doi:10.1002/ijc.10990
26. Schock H, Surcel HM, Zeleniuch-Jacquotte A, Grankvist K, Lakso HA, Fortner RT, Kaaks R et al (2014) Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer. Endocr Relat Cancer 21(6):831–844. doi:10.1530/ERC-14-0282
27. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR (1993) Design of the Fracture Intervention Trial. Osteoporos Int 3(Suppl 3):S29–S39
28. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077–2082
29. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927–2938. doi:10.1001/jama.296.24.2927
30. Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD, Ziegler RG (2007) Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 79(20):7813–7821. doi:10.1021/ac070494j
31. Barlow WE, Ichikawa L, Rosner D, Izumi S (1999) Analysis of case-cohort designs. J Clin Epidemiol 52(12):1165–1172
32. Eliassen AH, Hankinson SE (2008) Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 630:148–165
33. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, Krogh V et al (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 108(3):425–432. doi:10.1002/ijc.11529
34. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY, Levitz M et al (2001) Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 84(7):975–981. doi:10.1054/bjoc.2001.1704
35. Zahid M, Beseler CL, Hall JB, LeVan T, Cavalieri EL, Rogan EG (2014) Unbalanced estrogen metabolism in ovarian cancer. Int J Cancer 134(10):2414–2423. doi:10.1002/ijc.28565